MUNICH–(BUSINESS WIRE)–Isarna Therapeutics adds FDA orphan drug designation to its ISTH0036 program to treat prevention of scarring post glaucoma filtration surgery.
Author: Business Wire
LENSAR Receives CE Mark for Five New Performance Application Upgrades to the LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., announces receipt of the CE Mark for five application upgrades to the LENSAR® Laser System with Streamline™ for femtosecond cataract surgery.
Riassunto: LENSAR riceve il marchio CE per cinque nuovi aggiornamenti alle prestazioni dell’applicazione per il sistema laser LENSAR
ORLANDO, Florida–(BUSINESS WIRE)–LENSAR, Inc., leader a livello mondiale della tecnologia laser a femtosecondi di nuova generazione per la chirurgia refrattiva per cataratta, ha annunciato oggi di aver ricevuto il marchio CE da parte degli enti regolatori dell’Unione Europea per un pacchetto di cinque nuove tecnologie di applicazione integrate nel prodotto fiore all’occhiello della società, il sistema laser LENSAR®. Il testo originale del presente annuncio, redatto nella lingua di partenza, è
Research and Markets: Viral Conjunctivitis Pipeline Review, H1 2015 – 5 Companies & 7 Drug Profiles
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/lpfw62/viral) has announced the addition of the “Viral Conjunctivitis – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive inf…
NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary non-antibiotic antimicrobial products, will host an investment community conference call today, June 9th, 2015. Management will discuss the attributes of its FDA-cleared intelli-Case for safely disinfecting contact lenses with hydrogen peroxide announced in its press release issued
ZEISS Presents Its New Generation of Vascular Imaging: OCT Angiography
DUBLIN, Calif.–(BUSINESS WIRE)–ZEISS Presents Its New Generation of Vascular Imaging: OCT Angiography. Prolific research from ZEISS at the recent 2015 ARVO Meeting in Denver highlights the company’s standing as the leader in OCT.
Research and Markets: Global Ophthalmics Partnering Deal Trends, Players and Financials 2010-2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/pftvgh/global) has announced the addition of the “Global Ophthalmics Partnering 2010-2015: Deal trends, players and financials” report to their offering. The Glob…
Research and Markets: Global Ophthalmics Partnering Deals Report 2010-2015: Trends, Players and Financials of 400 Deals
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/tx2h7r/global) has announced the addition of the “Global Ophthalmics Partnering 2010-2015: Deal trends, players and financials” report to their offering. The Glob…
InSite Vision to Merge With Canadian Biotechnology Company QLT
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that it has reached a definitive agreement with QLT Inc. (NASDAQ: QLTI) (TSX: QLT) under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The transaction is expected to drive shareholder value by accelerating both companies’ development
QLT Announces Multiple Transactions Designed to Transform the Company and Create Significant Near- and Long-Term Value for Shareholders
VANCOUVER, British Columbia–(BUSINESS WIRE)–QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT” or the “Company”) announced today that it has signed definitive agreements on multiple separate transformative transactions and will be returning capital to shareholders. Together, these actions are expected to create significant liquidity and near- and long-term value for QLT shareholders. InSite Vision Acquisition: QLT has entered into a definitive agreement to acquire (the “InSite Acquisition”) InSite Visio
R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Cerebral Infarction Utilizing VAP-1 Inhibitor (RTU-009) with Autonomous University of Barcelona and Vall d’Hebron Institute of Research
TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ: 4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with Autonomous University of Barcelona (UAB) and Vall d’Hebron Institute of Research (VHIR), in Catalonia (Spain) to develop a novel VAP-1 inhibitor (Development code: RTU-009) for treatment of cerebral infarction. RTU-009 is a novel VAP-1 inhibitor, having an anti-inflammatory and neuroprotective effect. It is confirmed that RTU-009 has a neuroprotective effect similar to
Company Profile for Acucela Inc.
–(BUSINESS WIRE)–Acucela Inc. is a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, which could impact mi…
Avedro Announces 500th Cross-linking Device Sale Outside the US
WALTHAM, Mass.–(BUSINESS WIRE)–Avedro announces that it has sold its 500th cross-linking device outside of the United States. Study data presented on its non-surgical PiXL procedure shows promise for low myopia correction.
Terry Walsh Joins Renaissance as National Director of Sales and Market Development
INDIANAPOLIS–(BUSINESS WIRE)–Renaissance, a leading ancillary insurance carrier of customizable dental and vision plans, has hired industry veteran Terry Walsh as national director of sales and market development.
World Glaucoma Congress to Feature Symposium on XEN Gel Stent for Minimally Invasive IOP Reduction
ALISO VIEJO, Calif.–(BUSINESS WIRE)–AqueSys, Inc., manufacturers of the XEN Gel Stent, is hosting a symposium at the World Glaucoma Congress June 7 in Hong Kong to present the benefits of the minimally invasive device in reducing IOP.
FDA Clears NovaBay Pharmaceuticals’ New High-Tech Device, intelli-Case, for Safely Disinfecting Contact Lenses with Hydrogen Peroxide
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market, including revolutionary non-antibiotic antimicrobial products, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its novel intelli-Case with hydrogen peroxide solutions. Click here to view a presentation on intelli-Case. More than 24 million Americans n
Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, to…
Ophthotech Corporation to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 36th Annual Global Healthcare Conference on June 10, 2015.
Second Sight Appoints Matthew J. Pfeffer to Its Board of Directors
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that provide functional vision to blind patients, today annou…
EYE TECH CARE在中國發展業務，成為其全球擴張的一部分
法國RILLIEUX-LA-PAPE–(BUSINESS WIRE)–(美國商業資訊) — EYE TECH CARE SA (ETC)是開發和行銷眼科無創治療醫療器材的公司，該公司今天宣佈，其用於治療青光眼的創新系統EyeOP1®已獲得中國食品藥品監督管理局(CFDA)的醫療器械分類，開始審核流程。 繼EyeOP1®在歐洲和美國（EYE TECH CARE的主要目標市場）上市之後，中國成為該公司的關鍵市場：中國青光眼患者有2200萬人，占全球青光眼病例人數的28% (MarketScope 2014)。這些患者中多數為晚期青光眼，需要手術治療，由於手術步驟和病情的複雜性，手術後可導致各種併發症，手術需要由受過專科訓練的外科醫師在專科治療機構中進行。 EyeOP1®是ETC開發的創新醫學解決方案，用於治療青光眼，可替代手術治療。它可用於所有青光眼未獲控制的患者，無論患者既往是否接受過治療，可完全符合中國市場的需求。該治療為門診手術，可顯著降低眼內壓。該手術的原理是對睫狀體進行超音波處理（即手術治療），使眼睛的這一部位產生精確定位的輕微凝固，從而減少水性體液的生成。對醫師而言，該